Who Paid My Doc
A Phase 2B Multicenter, Randomized, Open-Label Study Comparing the Eff
Research payments
$4,440,476
Through program year 2024, $4,440,476 in research payments was reported against A Phase 2B Multicenter, Randomized, Open-Label Study Comparing the Eff, across 895 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $4,105,064 | 832 |
| 2023 | Research | $335,412 | 63 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Javier Morales Ramirez Santurce, PR Named on 56 payments
- Cornelius Van Dam Greensboro, NC Named on 53 payments
- Linda Gorgos Santa Fe, NM Named on 44 payments
- Princy Kumar Washington, DC Named on 40 payments
- Carl Fichtenbaum Cincinnati, OH Named on 38 payments
- Christopher Evans Portland, OR Named on 34 payments
- Ogechika Alozie El Paso, TX Named on 32 payments
- Zachary Henry Fort Lauderdale, FL Named on 31 payments
- Mitchell Whitehead Pensacola, FL Named on 29 payments
- Anthony Mills West Hollywood, CA Named on 27 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.